JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells
Authors
Keywords
-
Journal
BMC IMMUNOLOGY
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-15
DOI
10.1186/s12865-020-00365-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study
- (2020) Hideto Kameda et al. RHEUMATOLOGY
- Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
- (2018) Mark C Genovese et al. LANCET
- Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries
- (2018) Ernest Choy et al. RHEUMATOLOGY
- Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System
- (2018) Satoshi Kubo et al. Frontiers in Immunology
- OUP accepted manuscript
- (2018) RHEUMATOLOGY
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- Intracellular interleukin (IL)-1 family cytokine processing enzyme
- (2016) Areum Kwak et al. ARCHIVES OF PHARMACAL RESEARCH
- Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics
- (2016) Manathip Osiri et al. CLINICAL RHEUMATOLOGY
- Janus kinase inhibitors for rheumatoid arthritis
- (2016) Kunihiro Yamaoka CURRENT OPINION IN CHEMICAL BIOLOGY
- Network pharmacology of JAK inhibitors
- (2016) Devapregasan Moodley et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators
- (2015) Peng Zhan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting GM-CSF in inflammatory diseases
- (2015) Ian P. Wicks et al. Nature Reviews Rheumatology
- Type I/II cytokines, JAKs and new strategies for treating autoimmune diseases
- (2015) Daniella M. Schwartz et al. Nature Reviews Rheumatology
- Selective inhibitors of the Janus kinase Jak3—Are they effective?
- (2014) Gebhard Thoma et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Selective JAK inhibitors in development for rheumatoid arthritis
- (2014) Peter Norman EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
- (2014) James D. Clark et al. JOURNAL OF MEDICINAL CHEMISTRY
- Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings
- (2013) Violeta Yu et al. EXPERIMENTAL HEMATOLOGY
- Kinase inhibitors: a new approach to rheumatoid arthritis treatment
- (2010) Stanley Cohen et al. CURRENT OPINION IN RHEUMATOLOGY
- Treating inflammation with the Janus Kinase inhibitor CP-690,550
- (2010) Lalitha Vijayakrishnan et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Sensing pathogens and danger signals by the inflammasome
- (2009) Joao HF Pedra et al. CURRENT OPINION IN IMMUNOLOGY
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains
- (2009) Neal K. Williams et al. JOURNAL OF MOLECULAR BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now